What You Should Know
- Aidoc has raised $150M in Series E funding, led by Growth Equity at Goldman Sachs Alternatives, bringing its total funding to over $500M. The round included participation from General Catalyst, SoftBank Investment Advisors, and NVentures (NVIDIA’s venture capital arm).
- Capital will be used to further develop Aidoc’s CARE™ clinical foundation model and its aiOS™ enterprise platform.
- The company currently analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals worldwide.
- Aidoc recently received a landmark first FDA clearance for a comprehensive foundation model-based triage system in clinical imaging.
The clinical AI market is rapidly maturing, moving away from fragmented “point solutions” toward enterprise-wide platforms that can manage complex diagnostic decisions across entire health systems. Aidoc, a global leader in this space, has secured $150M in Series E funding to lead this transition. This investment—coming less than a year after a previous growth round—underscores the accelerating demand for AI that provides comprehensive disease coverage rather than tackling one use case at a time.
With diagnostic errors and delays contributing to at least 400,000 deaths annually in the U.S., the pressure on hospital imaging departments is at an all-time high. Aidoc’s strategy centers on its proprietary CARE™ foundation model, which enables expanded coverage across conditions and modalities from a single architecture, significantly reducing the “technical debt” of managing multiple standalone AI tools.
From Pixels to Draft Reports: The End-to-End Vision
The new capital will drive the next phase of Aidoc’s product roadmap: the move from automated triage to automated drafting. CEO Elad Walach has stated that within two years, the platform aims to support the full clinical workflow, from analyzing pixels to generating draft imaging reports. This end-to-end approach is designed to directly combat the workforce shortages and rising imaging volumes that currently plague modern radiology.
By 2030, Aidoc envisions a world where every complex diagnostic decision is supported by AI to ensure earlier detection and a reduction in preventable errors. To achieve this, the company is focusing heavily on regulatory discipline and governance frameworks, ensuring that as AI scales, it remains accountable and safe within real-world clinical environments.
Global Scale
As hospitals consolidate their standalone digital tools under centralized operating frameworks, Aidoc’s aiOS™ platform provides the “centralized operating layer” needed to govern and scale AI effectively. With nearly 2,000 hospitals already on the network, Aidoc is effectively building the digital infrastructure for the next generation of precision medicine.
